






Sepsis is a complex medical illness characterized by a deleterious pro-inflammatory response to an inciting infection leading to multi-system organ dysfunction. From a public health perspective, sepsis affects over one million Americans annually with considerable in-hospital mortality, substantial associated healthcare costs, and increased physical and neurocognitive deficits in survivors of sepsis hospitalizations. Dysglycemia during sepsis hospitalization – manifesting through either hypoglycemia, hyperglycemia, or increased glycemic variability –confers increased risk of organ dysfunction and death. Novel targets for the treatment of sepsis and maintenance of glucose homeostasis are needed.
The incretin hormone axis has emerged recently as a therapeutic target in the management of diabetes mellitus. The intestine-derived incretin hormones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted by enteroendocrine cells in response to enteral nutrients and potentiate insulin release from pancreatic beta cells in a glucose-dependent manner. Incretin hormones have additional pleiotropic effects on improving insulin sensitivity and reducing systemic inflammation. Medications targeting increased incretin activity are effective in improving glycemic control in diabetic patients and reducing cardiovascular risk.
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1.0 	The public health problem of sepsis
Sepsis is a life-threatening illness characterized by overwhelming systemic inflammation in response to an initial infectious insult. ADDIN EN.CITE 1,2 Pathogen-derived substances, such as the bacterial cell wall component lipopolysaccharide (LPS), injure host cells and release pathogen-associated molecular patterns (PAMPS) and damage-associated molecular patterns (DAMPS) which activate immune cells including neutrophils, macrophages, and lymphocytes resulting in the release of pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and tumor necrosis-alpha (TNF-α). ADDIN EN.CITE 3-6 The combination of pathogen-induced injury and systemic inflammation contribute to widespread multi-organ dysfunction in sepsis including acute lung injury, cardiovascular collapse, acute renal and liver failure, and abnormalities in the coagulation cascade. ADDIN EN.CITE 7-9 Higher pro-inflammatory cytokine levels early in the acute phase of sepsis have been associated with increased organ dysfunction and death. ADDIN EN.CITE 10,11
Sepsis is a leading cause of morbidity and mortality among hospitalized patients, particularly in the intensive care unit. ADDIN EN.CITE 12-14 Sepsis accounts for over 1 million hospitalizations in the United States per year, contributes to 1 out of every 2 to 3 hospital deaths, and is associated with over 27 billion dollars in healthcare costs annually. ADDIN EN.CITE 15,16 Approximately 25% of patients admitted with sepsis will die during their hospitalization, and 1 of 3 septic patients who survive to hospital discharge will die during the subsequent year. ADDIN EN.CITE 17 Additionally, sepsis survivors develop new cognitive and physical deficits that persist for years after their septic episode, as well as new or worsening mental health ailments related to their hospitalization. ADDIN EN.CITE 18,19 
Despite greater understanding into the pathophysiology of sepsis, to date, no sepsis-specific therapies have been successfully developed. Promising preclinical therapies agents including anti-TNF-α antibodies, anti-IL-1β antibodies, and activated protein C failed to demonstrate benefit in randomized clinical trials. ADDIN EN.CITE 20-22 Rather, the treatments that have demonstrated the greatest benefit have been the early use of antimicrobial agents and intravenous fluids. ADDIN EN.CITE 23-25 Critical care guidelines emphasize reducing delay to these life-saving therapies as late initiation is associated with worse outcomes. ADDIN EN.CITE 26 Novel strategies for the management of sepsis are needed to improve survival and long-term recovery.
2.0 	Disorders of glucose metabolism in sepsis
2.1	Harms of dysregulated glycemic control
Metabolic and endocrine derangements are common in critically-ill septic patients and are influenced both by the pathogenesis of the acute illness and by associated medical treatments. Septic patients, both diabetic and non-diabetic, may experience hyperglycemia during their hospitalization. The development of hyperglycemia in previously non-diabetic critically-ill patients, often referred to as “stress hyperglycemia,” complicates at least 12 percent of sepsis cases. The incidence of hyperglycemia during sepsis hospitalizations increases the risk of organ dysfunction and death. ADDIN EN.CITE 27-33 
The mechanisms underlying hyperglycemia during sepsis remain incompletely understood. Sepsis induces a hypermetabolic state in a background of injurious systemic inflammation.34 Pro-inflammatory cytokines released in the acute phase of sepsis, including IL-1β, TNF-α, and IL-6, induce peripheral insulin resistance by inhibiting the expression and membrane translocation of glucose transporter type 4 (GLUT4) and impairing insulin signaling through the insulin-receptor substrate-1 (IRS-1) and protein kinase B pathways. ADDIN EN.CITE 35-39 The acute effects of pro-inflammatory cytokines on pancreatic insulin release are conflicting with some studies demonstrating increased insulin release and others demonstrating suppression of insulin secretion. ADDIN EN.CITE 40-44 Regardless, prolonged exposure to pro-inflammatory cytokines is injurious to pancreatic β cells and triggers apoptosis. ADDIN EN.CITE 45-48
Medical therapy initiated for the management of septic patients also contributes to hyperglycemia.49 Vasopressors and glucocorticoids, typically initiated to treat sepsis-induced hypotension and dysregulation of the hypothalamic-pituitary adrenal axis, have been shown to induce hyperglycemia in septic animal models and human studies. ADDIN EN.CITE 50-54 Furthermore, the provision of supplemental nutrition, particularly when administered via the intravenous (or parenteral) route, may worsen glycemic control in sepsis. ADDIN EN.CITE 55,56 Distinguishing the separate contributions of pathophysiologic and iatrogenic factors in the development of hyperglycemia remains a challenge in clinical studies of sepsis.34
Once present, hyperglycemia impairs the function of the innate immune response and increases systemic inflammation. ADDIN EN.CITE 57,58 In neutrophils, for example, hyperglycemia decreases granule release, reduces neutrophil extracellular trap (NET) formation, and prevents effective chemotaxis resulting in reduced bactericidal capacity.59 In monocytes, high-glucose concentrations in cell culture medium increase expression of pro-inflammatory cytokines and vascular adhesion molecules.60 Acute hyperglycemia augments cytokine release from macrophages in response to LPS in vitro, and macrophages exposed chronically to hyperglycemia in mouse models and in human diabetic patients exhibit higher inflammatory states compared to macrophages from non-diabetic controls. ADDIN EN.CITE 61,62 Additionally, blood glucose in hyperglycemic states can complex with bacterial components and complement proteins thereby impairing the immune response by preventing effective phagocytosis and opsonization. ADDIN EN.CITE 63-65 
Hypoglycemia also complicates sepsis episodes and worsens outcomes. In clinical studies, hypoglycemia has been identified as an independent predictor of increased in-hospital and one-year mortality in critically-ill septic patients. ADDIN EN.CITE 66,67 Acute hypoglycemia in healthy individuals (both with and without diabetes mellitus) has been shown to increase oxidative stress, platelet aggregation, pro-inflammatory cytokine levels including IL-6, and vascular adhesion molecules including soluble vascular adhesion molecule-1 (sVCAM), intracellular adhesion molecule-1 (ICAM-1), and E-selectin. ADDIN EN.CITE 68-70 Similar effects are likely to be detrimental in the setting of acute sepsis. 
Lastly, the variation in blood glucose in critically-ill patients also has prognostic importance as increased glycemic variability during hospitalization for sepsis is associated with higher in-hospital mortality. ADDIN EN.CITE 67,71-73
2.2	Clinical trials of glycemic control
The discovery of the adverse effects of dysglycemia in critical illness prompted several large randomized-controlled clinical studies. A landmark study published by van den Berghe and colleagues in 2001 demonstrated a significant mortality benefit with the use of exogenous intravenous insulin to maintain tight glycemic control (blood glucose maintained between 80 and 100 mg/dL) in a mixed population of medical and surgical critically-ill patients. ADDIN EN.CITE 31 Subsequent studies did not demonstrate the same benefit. ADDIN EN.CITE 74-78 The multi-center normoglycemia in intensive care evaluation–survival using glucose algorithm regulation study (NICE-SUGAR) published in 2009 compared tight glycemic control to a protocol maintaining blood glucose in a higher range (less than 180 mg/dL) and demonstrated increased mortality in the tight glycemic control group.75 Increased incidence of hypoglycemia in the tight glycemic control arm has been proposed as a potential mechanism for higher mortality, and two subsequent studies – the VISEP trial and the GLUCONTROL trial – were stopped early due to increased hypoglycemia in the treatment arms. ADDIN EN.CITE 76-78 Importantly, the patients with the best outcomes in these studies are the ones that remained euglycemic without the need for supplemental insulin. Novel strategies to maintain euglycemia without increased risk of hypoglycemia are needed. 
3.0 	The incretin hormone axis
3.1	Function of incretin hormones
Incretin hormones have recently emerged as an important therapeutic target in the management of diabetes mellitus. The “incretin effect” has been described since the early 1900s and refers to the phenomenon whereby an oral glucose load promotes a greater increase in insulin secretion and lower blood glucose levels than an equivalent glucose load delivered by the intravenous route. Several decades later, the intestine-derived incretins were identified as the hormones responsible for this nutrient-dependent increase in insulin secretion.79 
Incretins are a family of intestine-derived hormones that are secreted in response to enteral nutrients. Incretins are primarily released in response to carbohydrates and lipids, but incretin release has also been described in response to amino acids and short-chain fatty acids. The incretin hormones include glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), glicentin, and oxyntomodulin. GIP is encoded by the GIP gene, while the other incretins are derived from alternative splicing by prohormone convertase 1/3 (PC1/3) of the preproglucagon peptide encoded by the Gcg gene. GIP and GLP-1 were the first incretins to be characterized and have been the most intensely studied. ADDIN EN.CITE 80-82
GIP and GLP-1 each promote glucose-dependent insulin secretion from pancreatic β cells in response to enteral nutrients. GLP-1 has additional roles (which GIP does not) in suppressing glucagon release under conditions of euglycemia and hyperglycemia, inducing satiety in response to meals, and increasing β cell proliferation. GIP is released from a group of enteroendocrine cells referred to as K cells located primarily in the proximal small intestine. GLP-1 is released from enteroendocrine L cells located in the distal small bowel and large colon. Serum levels of GIP and GLP-1 rise within 15 to 30 minutes after ingestion of a meal. While the rapid increase in GIP is likely due to direct stimulation of K cells by enteral nutrients, the increase in GLP-1 is believed to be related to vagal stimulation along enteral neuronal pathways. A second peak in GLP-1 secretion is noted up to an hour after meal ingestion and has been attributed to a delayed presentation of enteral nutrients to K cells in the distal small bowel. Incretins have a short half-life and are rapidly degraded by the protease dipeptidyl-peptidase IV (DPP IV) upon release. GIP has a half-life of 7-8 minutes in human serum and GLP-1 has a half-life of 3-4 minutes. ADDIN EN.CITE 79,80,83-87 
The receptors for GIP and GLP-1 (GIPR and GLP-1R respectively) are seven-transmembrane G-protein coupled receptors that increase cyclic adenosine monophosphate (cAMP) and intracellular calcium in response to ligand binding through both phosphokinase A (PKA) dependent and independent mechanisms. ADDIN EN.CITE 88,89 In pancreatic β cells, GIPR and GLP-1R signaling induce insulin exocytosis, increase insulin gene expression, and improve insulin mRNA stability. GIPR and GLP-1R have been detected in the pancreas, small and large intestine, adipose tissue, central nervous system, as well as in mouse and human immune cells ADDIN EN.CITE 90,91, although concern has been raised about the specificity of several GIPR and GLP-1R antisera in commercial use. ADDIN EN.CITE 92 Single nucleotide polymorphisms in GIPR and GLP-1R have been associated with altered risk for the development of diabetes mellitus. ADDIN EN.CITE 93
While not as extensively characterized, GLP-2 and glicentin are believed to be secreted from L cells by the same stimuli that induce GLP-1 release.94 GLP-2 demonstrates local anti-inflammatory effects in the intestine and potentially helps maintain the integrity of the intestinal epithelial barrier.95 The biologic roles of GLP-2, glicentin, and oxyntomodulin under physiologic conditions are areas of ongoing research.
3.2	Incretin-based therapies in diabetes mellitus
Therapies targeting increased incretin activity are FDA approved for the treatment of diabetes mellitus. Preliminary studies suggested that GIP signaling is decreased in diabetic patients, thus, GLP-1 based therapies predominate. ADDIN EN.CITE 96,97 Two main categories of incretin-based therapy are currently in use: incretin mimetics and DPP-4 inhibitors. Incretin mimetics including exenatide, liraglutide, and semaglutide are structurally similar to GLP-1 but have been modified to prevent degradation by DPP4. Incretin mimetics have a lower risk of hypoglycemia compared to older incretin secretagogues such as sulfonylureas. The DPP-4 inhibitors including sitagliptin and linagliptin increase incretin levels by blocking protease degradation by DPP-4, thus increasing endogenous levels of both GIP and GLP-1. ADDIN EN.CITE 98-100 As DPP-4, also known as CD26, is a ubiquitously expressed protein existing in both soluble and membrane-bound forms in numerous tissues (including roles in the immune response), debate remains as to whether the glucose-lowering effects of DPP-4 inhibitors are solely due to increases in GIP and GLP-1 or whether other potential DPP-4 substrates contribute. ADDIN EN.CITE 101,102
Incretin mimetics and DPP-4 inhibitors both improve glycemic control and reduce hemoglobin A1c (HbA1c) levels in patients with diabetes mellitus type 2. Incretin mimetics increase weight loss in overweight patients providing additional benefit by reducing the adverse effects of obesity on glucose metabolism, and may also improve glycemic control in patients with diabetes mellitus type 1 that retain some endogenous insulin production. ADDIN EN.CITE 103,104 
Recent clinical trials have highlighted a cardioprotective effect of incretin mimetic therapy. ADDIN EN.CITE 105,106 The landmark Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) study randomized 9340 diabetic patients with pre-existing cardiovascular disease to liraglutide or placebo arms in addition to usual care with a composite primary outcome of time to cardiovascular death, non-fatal myocardial infarction, and non-fatal cerebrovascular accident. Liraglutide significantly increased time to primary outcome with reductions in both cardiovascular mortality and all-cause mortality. Less hypoglycemic events were noted in the liraglutide arm compared to usual care with placebo. The number needed to treat in this trial to prevent one cardiovascular event was 66 and to prevent one death was 98. ADDIN EN.CITE 107 The subsequent Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6) tested the effects of semaglutide over a placebo control in addition to usual care in 3297 diabetic patients and similarly demonstrated significant reductions in a composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Patients in the semaglutide group had additional decreases in weight, in HbA1c, and in antihypertensive use compared to the placebo group without an increase in hypoglycemia. ADDIN EN.CITE 108 The cardioprotective effects appear to be medication-specific as not all incretin mimetic therapies have demonstrated cardiovascular benefit, nor have DPP-4 inhibitors demonstrated similar effects. ADDIN EN.CITE 109 The cardioprotective effects of incretin mimetics have influenced medication management in diabetes with several clinical practical guidelines recommending early initiation in patients at risk for cardiovascular disease. ADDIN EN.CITE 110,111 Incretin-based therapies have revolutionized the chronic treatment of diabetes mellitus, and their beneficial effects on systemic inflammation make them potential targets in acute illness as well.

	
4.0 	Effects of incretin hormones on inflammation 
4.1	Incretin release in response to inflammatory stimuli
Although incretins are secreted by enteroendocrine cells in response to enteral nutrients, recent studies revealed that incretins are also released in response to inflammatory stimuli. Studies by Ellinsgaard and colleagues in murine and human cell lines demonstrate that IL-6 acutely stimulates GLP-1 production in pancreatic α cells and in immortalized enterendocrine GLUTag cells in a dose-dependent manner mediated by increases in Pcsk1 (encoding PC1/3) and Gcg gene expression. IL-6 stimulated GLP-1 production is dependent on signaling through the janus kinase 2 (JAK2) and signal transduction and activator of transcription 3 (STAT3) pathways. Systemic IL-6 administration to mice improves glucose disposal, increases insulin secretion, and increases circulating GLP-1 in oral glucose tolerance tests, and these improvements with IL-6 are not noted in mice deficient for the GLP-1 receptor. ADDIN EN.CITE 40 Subsequent studies confirmed the ability of IL-6 to increase GLP-1 in mice and also demonstrated the potential for IL-1β to increase GLP-1 levels. ADDIN EN.CITE 41 The bacterial cell wall component LPS (often used as an inflammatory stimulus in sterile models of sepsis) increases GLP-1 through an IL-6 dependent mechanism and additionally increases GIP through an IL-1β dependent mechanism. ADDIN EN.CITE 41,112,113 
The role of incretin hormones in the response to systemic inflammation is unclear but a recent study by Lebrun and colleagues demonstrates that GLP-1 is released from L cells in response to dextran sodium sulfate (DSS) and ischemia reperfusion of the gut. ADDIN EN.CITE 114 Given the local effects of GLP-1 and GLP-2 on intestinal epithelium, enteroendocrine cells may act as biologic damage sensors and release incretins in response to intestinal injury as a means to improve barrier integrity during systemic inflammation, but further studies are necessary to characterize the role of incretins in this regard. ADDIN EN.CITE 115-118 
4.2	Effects of incretins on activated immune cells
While they are released in response to inflammatory stimuli, incretins consistently demonstrate anti-inflammatory effects.119 Incretin receptors have been detected in immune cells including macrophages, monocytes, and B and T cell lymphocytes. ADDIN EN.CITE 92,120 Yusta and colleagues demonstrated that exendin-4, a GLP-1 receptor agonist, reduces pro-inflammatory cytokine expression in a specialized group of activated intestinal intraepithelial lymphocytes influencing the immune response to injury. Lack of GLP-1 receptor signaling in this study in GLP-1R knockout (KO) mice increases severity of intestinal injury in response to DSS and alters the intestinal microbiome composition, while restoration of GLP-1 signaling through bone marrow transplantation in GLP-1R KO mice rescues intestinal integrity. ADDIN EN.CITE 118 Treatment of cultured macrophages with exendin-4 attenuates the inflammatory response to LPS through a phosphokinase A (PKA)-cAMP dependent pathway with decreased nuclear translocation of nuclear factor kappa B (NFκB) and reductions in IL-6, IL-1β, and TNF-α. ADDIN EN.CITE 121,122 Exendin also increases macrophage production of IL-10 and arginase ADDIN EN.CITE 122, suggesting GLP-1R agonism can influence polarization shifting from the M1 classically-activated pro-inflammatory phenotype to the M2 anti-inflammatory phenotype.123 The DPP-4 inhibitor anagliptin similarly reduces mRNA expression of IL-6, TNF-α, IL-1β, and IL-12 in cultured macrophages exposed to LPS, associated with decreases in c-Jun N-terminal (JNK) and p38 signaling pathways, and with consistent results in cultured adipocytes. ADDIN EN.CITE 124 In cultured macrophages stimulated by oxidized low-density lipoprotein (ox-LDL), DPP-4 inhibitors reduces Nod-like receptor protein-3 (NLRP-3) and IL-1β production dependent on signaling through the GLP-1 receptor. ADDIN EN.CITE 125
Though not as well characterized, GLP-2 has anti-inflammatory actions as well, primarily on local intestinal epithelium. In murine models of intestinal injury, GLP-2 exerts IL-10 independent anti-inflammatory effects and helps preserve epithelial integrity through enteric neuronal pathways. ADDIN EN.CITE 126,127 Importantly, in a study of LPS-stimulated peritoneal macrophages, GLP-2 dose-dependently decreased pro-inflammatory cytokine and inducible nitric oxide synthase (iNOS) expression mediated by repression of NFκB through mitogen-activated protein (MAP) kinase signaling pathways. ADDIN EN.CITE 128
4.3	Systemic anti-inflammatory effects of incretin hormones
The anti-inflammatory effects of incretin-based therapies have been demonstrated in several cell and tissue types. In human aortic endothelial cells, treatment with liraglutide decreases expression of vascular adhesion molecules and reduces adhesion of monocytes induced by LPS or TNF-α insults ADDIN EN.CITE 129, with similar effects in human vascular endothelial cells stimulated by TNF-α. ADDIN EN.CITE 130 In cardiomyoblasts, treatment with liraglutide in a two-hit TNF-α and hypoxia model decreases NLRP3 inflammasome activation associated with improvements in cell viability.131 In LPS-stimulated cardiomyocytes, the DPP-4 inhibitor sitagliptin decreases NF-κB signaling and decreases TNF-α, IL-6, and IL-1β expression.132 Incretin infusions with either GIP or GLP-1 in mouse models significantly reduce vascular inflammation and decrease macrophage infiltration into the endothelium, consistent with findings that incretin-based therapies attenuate atherosclerotic plaque development. ADDIN EN.CITE 133-138 
Anti-inflammatory effects of incretin mimetics and DPP-4 inhibitors have been further demonstrated in adipose tissues ADDIN EN.CITE 139,140, pancreatic islets ADDIN EN.CITE 141-145, hepatocytes ADDIN EN.CITE 119,146,147, and renal glomerular cells ADDIN EN.CITE 148-151 in both in vitro and in vivo preclinical studies. Some studies suggest GIP may worsen inflammation from adipose tissues in obese individuals ADDIN EN.CITE 152,153, however, recent studies with novel GIP analogs suggest anti-inflammatory effects ADDIN EN.CITE 154,155, as do studies with DPP-4 inhibitors which raise levels of both GIP and GLP-1. ADDIN EN.CITE 145,156 Interestingly, GIP and GLP-1 analogs are being explored as therapeutic agents to reduce neuroinflammation in murine models of neurocognitive disorders including Alzheimer’s disease and Parkinson’s disease with preclinical findings of decreased cytokine production, inhibition of microglial cell activation, improved neuronal insulin sensitivity, and improved performance on cognitive testing. ADDIN EN.CITE 157-164
Anti-inflammatory effects of incretin-based therapies have been confirmed in clinical studies. An acute 3-hour infusion of exogenous GLP-1 reduced circulating IL-6 levels in a small study of obese individuals with diabetes mellitus type 2 with a trend towards reduced inflammation with GIP infusion as well. ADDIN EN.CITE 165 Chronic incretin mimetic use in diabetic patients decreases circulating pro-inflammatory cytokines including IL-6, TNF-α, IL-1β and monocyte chemoattractant protein-1 (MCP-1) with effects noted as early as 8 to 12 weeks and persisting anti-inflammatory effects reported 6 to 12 months after initiating treatment. ADDIN EN.CITE 166-169 Chronic DPP-4 use similarly decreases pro-inflammatory cytokines and vascular adhesion modules and increases anti-inflammatory mediators including IL-10. ADDIN EN.CITE 170,171 Given their anti-inflammatory effects, incretins hold promise as potential targets in sepsis.


5.0 	Incretins in preclinical models of sepsis
Several studies have examined the use of incretin-based therapies as therapeutic agents in mouse models of sepsis. As demonstrated in an endotoxemic rat study by Yanay and colleagues, the GLP-1 analog exendin-4 decreases circulating IL-6, TNF-α, IL-1β, and interferon-γ levels and prevents LPS-induced hypoglycemia.172 A subsequent study by Steven and colleagues demonstrates that both the incretin mimetic liraglutide and the DPP-4 inhibitor linagliptin decrease mortality in a severe endotoxemic rat model. In this study, both pretreatment before LPS and medication administration after the LPS insult confer protective effects. Both treatments improve LPS-induced hypotension, suppress pro-inflammatory markers in blood and in aortic cells, reduce oxidative stress, and improve LPS-related coagulation abnormalities. ADDIN EN.CITE 173 In endotoxemic mice, linagliptin and liraglutide reduce oxidative stress and suppress inflammatory markers in whole blood and in aortic cells, and also prevent LPS-induced thrombocytopenia and reduce microvascular thrombosis in the pulmonary vasculature. Protection against LPS-induced thrombocytopenia is also noted in mice deficient in DPP-4, while the beneficial effects of linagliptin and liraglutide are lost in mice deficient for the GLP-1 receptor. ADDIN EN.CITE 173 
Benefit with incretin mimetics is also noted in a cecal-ligation and puncture (CLP) model of sepsis whereby high dose exendin-4 administered twice daily starting 16 hours after septic insult improves survival, associated with decreases in the pro-inflammatory protein high mobility group box protein-1 (HMGB-1).174 In a separate study, long-lasting polyethylene-glycol (PEG) conjugated exendin-4 reduces lung injury, lowers IL-6, IL-1β, TNF-α, and MCP-1 levels, decreases peritoneal leukocyte counts, and reduces mortality following CLP. ADDIN EN.CITE 175 Incretin mimetics also decrease vascular permeability and inflammatory signaling in human umbilical vein endothelial cells (HUVEC) exposed to LPS.  ADDIN EN.CITE 174,175 The anti-inflammatory effect of incretin-based therapies following systemic exposure to LPS in vascular tissues, as well as improvements in cardiac function, have been confirmed in other preclinical studies. ADDIN EN.CITE 176,177 Furthermore, infusion of GLP-1 following intravenous LPS exposure reduces permeability in mesenteric vasculature, suggesting a protective effect against intestinal injury in settings of systemic inflammation. ADDIN EN.CITE 178
Recently, our laboratory demonstrated that infusion of low-level enteral dextrose in a murine endotoxemia model improves glucose disposal and insulin sensitivity, increases insulin secretion, improves mean arterial blood pressure, and decreases systemic inflammation mediated by critical increases in circulating GIP. When GIP signaling is inhibited with pharmacologic blockade, the beneficial effects of enteral dextrose are lost. Similar to prior preclinical sepsis studies, infusion of exogenous GIP in our model improves glucose disposal and reduces IL-6 levels in endotoxemic mice. Importantly, our study demonstrates that targeting of endogenous incretin hormones in the acute phase of sepsis may be achieved through provision of enteral nutrients.179 The preclinical findings of improved outcomes with endogenous incretin stimulation and with incretin-based therapy provision support the hypothesis that increased incretin activity is of potential clinical benefit to patients presenting with sepsis.

6.0 	Trials of incretin-therapies in the critically ill
A recent review on the intensive care medicine research agenda in nutrition and metabolism highlighted the role of GLP-1 and its agonists as an area needing further research in clinical studies. ADDIN EN.CITE 180 A small case control study explored changes in the incretin effect in critically ill patients compared to healthy controls by measuring differences in oral glucose tolerance tests (OGTT) versus intravenous glucose tolerance tests (IVGTT). The incretin effect was present but was decreased from a 57% increase in insulin in OGTT versus IVGTT in healthy controls to 23% in critically ill patients. OGTT results were similar between critically ill patients and controls suggesting intact enteroendocrine cell function, but critically ill patients had higher insulin responses in the IVGTT, potentially reflecting insulin resistance. In this study, GIP and glucagon were increased in critically ill patients compared to healthy controls, but GLP-1 was not. ADDIN EN.CITE 181 An observational cohort study monitoring changes in insulin sensitivity during critical illness suggested that initiation of enteral nutrition may induce the incretin effect, however, incretin levels were not directly measured in this study. 
Observational studies have demonstrated that GLP-1 levels are elevated in critically ill patients, particularly those admitted with sepsis, but these increased levels may be secondary to inflammation stimulating incretin release. ADDIN EN.CITE 41,182,183 In a study of 22 non-diabetic patients admitted for cardiac surgery with bypass or extracorporeal membranous oxygenation, increases in systemic IL-6 following surgery predicted subsequent increases in GLP-1. ADDIN EN.CITE 182 In a cohort study comparing healthy controls to critically-ill patients, GLP-1 levels were 6 fold higher in critically ill patients and were positively correlated with inflammatory markers including c-reactive protein and procalcitonin, as well as markers of organ dysfunction including cystatin C and coagulation factors. Increased GLP-1 levels in this study independently predicted intensive care unit (ICU) mortality in the critically ill cohort, of which 66% presented with sepsis. ADDIN EN.CITE 183 
Several small clinical trials have been conducted testing the effect of exogenous incretins in critical illness. In cardiac and in mixed medical and surgical intensive care unit populations, exogenous GLP-1 is effective in reducing blood glucose and glycemic variability compared to placebo without an increased risk of hypoglycemia. ADDIN EN.CITE 184-190 Infusion of the GLP-1 analog exenatide may similarly improve glycemic control but has been associated with significant gastrointestinal side effects. ADDIN EN.CITE 191 Despite being well-tolerated, infusions of exogenous GIP have not demonstrated benefit in reducing blood sugar in critically ill patients, but in these studies the effects of GIP were tested in the fasted state, where glucose-stimulated insulin secretion may be blunted, and in response to a liquid meal bolus, which already stimulates endogenous incretin hormone production. ADDIN EN.CITE 192,193 Notably, these clinical trials were performed mostly in mixed ICU populations and as detailed in Table 1, few septic patients were enrolled in these studies. Further clinical trials are needed to better characterize the incretin hormone axis during sepsis and to determine a potential therapeutic role. A prospective single-center double-blind placebo-controlled randomized clinical trial from our laboratory is currently recruiting patients to define the effects of a low-level enteral dextrose infusion on inflammation and on endogenous incretin hormone production in critically ill septic patients (NCT03454087). 

7.0 	Discussion
Incretin hormones represent an attractive therapeutic target in the care of acutely ill septic patients. Incretin-based therapies have revolutionized the chronic management of diabetic patients by providing a means to improve glycemic control, mitigate the risk of hypoglycemia, increase weight loss, improve insulin sensitivity, and reduce the risk of cardiovascular disease. 
Therapies targeting increased incretin activity may provide similar benefit in the care of critically ill septic patients. Since incretin hormones increase insulin secretion from pancreatic beta cells in a glucose-dependent manner, therapies targeting incretins may reduce the incidence of hyperglycemia and decrease glycemic variability during sepsis with a lower risk of hypoglycemia compared to conventional insulin treatment algorithms. Preclinical studies suggest additional benefits with incretin-based therapies. Incretin-mimetics and DPP-4 inhibitors attenuate the pro-inflammatory response in activated immune cells with additional anti-inflammatory effects in various tissues including vascular endothelium, adipose tissue, pancreatic islets, and hepatocytes. Furthermore, incretin-based therapies decrease systemic inflammation, limit organ dysfunction, and improve survival in sterile and bacteremic models of sepsis, but have not been validated in human studies.






















Table 1: Clinical Trials of Exogenous Incretion Therapies
Study	Year	Design	Population	Number of Participants	Participants with Sepsis	Treatment	Primary Results	Adverse Effects
Sokos et al ADDIN EN.CITE 189	2007	Double-blind placebo-controlled randomized clinical trial	Cardiac patients undergoing coronary artery bypass grafting	20	Not reported	GLP-1 infusion	Reduced blood glucose, insulin requirements, and cardiac arrhythmias	Hypoglycemia in 1 patient in GLP-1 group and 2 patients in placebo group
Deane et al ADDIN EN.CITE 188	2009	Double-blind placebo-controlled randomized crossover study	Mixed medical-surgical non-diabetic patients	7	Not reported	GLP-1 infusion	Reduced blood glucose	None
Deane et al ADDIN EN.CITE 184	2010	Double-blind placebo-controlled randomized crossover study	Mixed medical-surgical non-diabetic patients	25	4	GLP-1 infusion	Reduced blood glucose and small intestine glucose uptake	Hyperglycemia in 1 patient in GLP-1 group and 2 in placebo group
Deane et al ADDIN EN.CITE 185	2011	Double-blind placebo-controlled randomized crossover study	Mixed medical-surgical diabetic patients	11	5	GLP-1 infusion	Reduced in blood glucose 	None
Abuannadi et al ADDIN EN.CITE 191	2012	Single-center feasibility study, all patients received intervention	Cardiac intensive care unit patients	40	Not reported	GLP-1 infusion	Blood glucose control similar to historical controls receiving insulin infusion protocols targeting blood glucose 100 to 140 mg/dL	Hyperglycemia in 3 patients, hypoglycemia in 4, nausea in 16, emesis in 2
Lee et al ADDIN EN.CITE 193	2013	Double-blind placebo-controlled randomized crossover study	Mixed medical-surgical non-diabetic patients	20	9	GIP infusion in patients already receiving GLP-1 infusion	No additional effect on blood glucose	None
Galiatsatos et al ADDIN EN.CITE 187	2014	Double-blind placebo-controlled randomized clinical trial	Surgical and burn intensive care unit patients	18	Not reported	GLP-1 infusion	Reduced blood glucose and glycemic variability	Hypoglycemia in 1 patient in GLP-1 group and 3 in placebo group
Kar et al ADDIN EN.CITE 192	2015	Double-blind placebo-controlled randomized crossover study	Mixed medical-surgical non-diabetic patients	20	2	GIP infusion	No effect on blood glucose or gastric emptying	None
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